SEPSIS DIAGNOSTICS MARKET ANALYSIS

Sepsis Diagnostics MarketSize and Trends

The global sepsis diagnostics market is estimated to be valued at US$ 841.4 million in 2023 and is expected to exhibit a CAGR of 9.9% during the forecast period (2023-2030).

Figure 1. Global Sepsis Diagnostics Market Share (%), By Product Type, 2023

Global Sepsis Diagnostics Market– Drivers

The increasing prevalence of infectious diseases is expected to propel the growth of the global sepsis diagnostics market over the forecast period. For instance, on July 19, 2023, according to the World Health Organization (WHO), regional disparities in sepsis incidence and mortality existed; approximately 85% of sepsis cases and sepsis-related deaths worldwide occurred in low- and middle-income countries. Health care-associated infections are one of the most frequent types of adverse events to occur during care delivery and affect hundreds of millions of patients worldwide every year.

Increasing product approvals by regulatory authorities

Increasing product approvals by regulatory authorities is expected to drive the growth of the global sepsis diagnostics market in the near future. For instance, on January 18, 2023, Cytovale, a medical diagnostics company, announced that its IntelliSep test has received U.S. Food and Drug Administration (FDA) 510(k) clearance to aid in the early detection of sepsis for the approximately 30 million adult patients with signs and symptoms of infection who present to US emergency departments (ED) each year.

Figure 2. Global Sepsis Diagnostics Market Share(%), By Region, 2023

Market- Trends

The introduction of research and development with advanced technology in the market is expected to drive growth of the global sepsis diagnostics market over the forecast period. For instance, on October 28, 2022, DeepUll, a Spanish molecular diagnostics company, focused on developing molecular test to guide therapy selection for patients with sepsis. The DeepUll Company announced that it raised US$ 14.2 million in Series B financing to fund its efforts to offer a multiplex PCR-based alternative to blood culture, still the go-to technology for diagnosing and treating sepsis patients.